[141] conducted an IVM study on a mouse melanoma model and revealed that the combination of anti‐CTLA4 antibody and anti‐PD‐L1 antibody enhanced the motility of T cells to a greater degree than anti‐PD‐L1 alone. Here, CTLA4 is linked to melanoma.